Researchers have figured out a way to make an RNA biosensor that fluoresces when it encounters small inorganic metabolites—not by engineering the RNA but by adjusting its fluorogenic ligand molecule.

Aptamer Group plc, the developer of novel Optimer ® binders to enable innovation in the life sciences industry, today announces the signing of a new development contract with a rare disease ...

Cell-surface proteins are critical therapeutic targets and are vital to cellular communication, signaling, and homeostasis. However, developing high-affinity probes such as aptamers against these ...

Molecular dynamics simulations calculate the structure of p53m and its binding interfaces with p53-R175H and CRBN (a), and PAGE electrophoresis confirms the successful connection between p53m-DA and ...

Continuous monitoring of biomarkers is essential for early disease detection, treatment evaluation, and personalized health ...

In biology, many RNA molecules act as sophisticated microscopic machines. Among them, riboswitches function as tiny ...

In this roundtable discussion, an expert panel will discuss how the latest applications of aptamer technology are enabling innovation across the life sciences by replacing antibodies. Accurate ...

(RTTNews) - Aptamer Group (P0J.F, APTA.L) and Alphazyme, a Maravai LifeSciences (MRVI) company, have entered into a licensing agreement for a developed Optimer for use in hot-start PCR applications.